Natixis Biomarin Pharmaceutical Inc Transaction History

Natixis

  • $17.4 Billion
  • Q2 2024

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$83.81 - $99.0 $20.7 Million - $24.5 Million
-247,093 Reduced 85.97%
40,315 $3.52 Million
Q4 2023

Feb 13, 2024
SELL
$76.22 - $98.51 $16.1 Million - $20.8 Million
-211,293 Reduced 42.37%
287,408 $27.7 Million
Q3 2023

Nov 14, 2023
BUY
$85.07 - $94.48 $37.2 Million - $41.3 Million
436,729 Added 704.72%
498,701 $44.1 Million
Q2 2023

Aug 11, 2023
SELL
$86.68 - $100.3 $797,716 - $923,060
-9,203 Reduced 12.93%
61,972 $5.37 Million
Q1 2023

May 12, 2023
SELL
$87.74 - $117.27 $10,265 - $13,720
-117 Reduced 0.16%
71,175 $6.92 Million
Q4 2022

Feb 24, 2023
SELL
$80.93 - $108.63 $5.49 Million - $7.38 Million
-67,898 Reduced 48.78%
71,292 $7.38 Million
Q4 2022

Feb 13, 2023
SELL
$80.93 - $108.63 $6.43 Million - $8.63 Million
-79,438 Reduced 36.33%
139,190 $14.4 Million
Q3 2022

Nov 14, 2022
SELL
$82.16 - $96.94 $410,800 - $484,700
-5,000 Reduced 2.24%
218,628 $18.5 Million
Q2 2022

Aug 12, 2022
SELL
$71.48 - $86.85 $44.3 Million - $53.8 Million
-619,214 Reduced 73.47%
223,628 $18.5 Million
Q1 2022

May 13, 2022
SELL
$74.28 - $92.69 $3.13 Million - $3.9 Million
-42,084 Reduced 4.76%
842,842 $65 Million
Q4 2021

Feb 14, 2022
SELL
$71.72 - $91.47 $29.2 Million - $37.2 Million
-407,019 Reduced 31.5%
884,926 $78.2 Million
Q3 2021

Nov 12, 2021
BUY
$74.77 - $85.47 $5.93 Million - $6.78 Million
79,355 Added 6.54%
1,291,945 $99.9 Million
Q2 2021

Aug 13, 2021
BUY
$75.51 - $84.79 $4.38 Million - $4.92 Million
57,971 Added 5.02%
1,212,590 $101 Million
Q1 2021

May 14, 2021
SELL
$74.73 - $90.69 $20 Million - $24.2 Million
-267,391 Reduced 18.8%
1,154,619 $87.2 Million
Q4 2020

Feb 12, 2021
BUY
$72.61 - $90.2 $58 Million - $72.1 Million
799,207 Added 128.32%
1,422,010 $125 Million
Q3 2020

Nov 12, 2020
BUY
$71.87 - $131.03 $28.3 Million - $51.5 Million
393,237 Added 171.3%
622,803 $47.4 Million
Q2 2020

Aug 13, 2020
SELL
$79.55 - $124.22 $10.1 Million - $15.7 Million
-126,545 Reduced 35.54%
229,566 $28.3 Million
Q1 2020

May 14, 2020
SELL
$71.37 - $96.85 $2.24 Million - $3.03 Million
-31,316 Reduced 8.08%
356,111 $30.1 Million
Q4 2019

Feb 14, 2020
SELL
$64.27 - $86.37 $11.6 Million - $15.6 Million
-180,783 Reduced 31.82%
387,427 $32.8 Million
Q3 2019

Nov 13, 2019
BUY
$67.4 - $85.11 $12,603 - $15,915
187 Added 0.03%
568,210 $38.3 Million
Q2 2019

Aug 13, 2019
SELL
$80.35 - $93.9 $8.38 Million - $9.79 Million
-104,288 Reduced 15.51%
568,023 $48.7 Million
Q1 2019

May 15, 2019
BUY
$84.2 - $98.62 $11.3 Million - $13.2 Million
133,829 Added 24.85%
672,311 $59 Million
Q4 2018

Feb 14, 2019
BUY
$80.14 - $106.07 $1.69 Million - $2.23 Million
21,053 Added 4.07%
538,482 $45.9 Million
Q3 2018

Nov 14, 2018
BUY
$93.92 - $105.72 $48.6 Million - $54.7 Million
517,429 New
517,429 $50.2 Million
Q3 2017

Nov 14, 2017
SELL
$80.6 - $94.95 $987,914 - $1.16 Million
-12,257 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
12,257
12,257 $1.11 Million

Others Institutions Holding BMRN

# of Institutions
632
Shares Held
185M
Call Options Held
1.63M
Put Options Held
1.2M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.1B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email